drugset / Trial / NCT01263002

A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC

NCT01263002

Phase 4 Completed 33 enrolled Bukwang Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

An open study to evaluate the Efficacy, Safety of Clevudine monotherapy or Adefovir and Clevudine combination in Proportion to Roadmap Concept in patients with chronic hepatitis B Associated Hepatocellular Carcinoma

Timeline

Start
2010-06
Primary completion
2013-01
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Adefovir Unknown 10 mg
Subject Clevudine Small molecule 30 mg